No association between the aluminium content of trabecular bone and bone density, mass or size of the proximal femur in elderly men and women

BACKGROUND: Aluminium is considered a bone toxic metal since poisoning can lead to aluminium-induced bone disease in patients with chronic renal failure. Healthy subjects with normal renal function retain 4% of the aluminium consumed. They might thus also accumulate aluminium and eventually be at risk of long-term low-grade aluminium intoxication that can affect bone health. METHODS: We therefore examined 62 patients with femoral neck fractures or osteoarthritis of the hip (age range 38–93), with the aim of examining whether aluminium in bone is associated with bone-mineral density (BMD), content (BMC) or width of the femoral neck measured by dual-energy X-ray absorptiometry (DXA). During operations bone biopsies were taken from the trabecular bone of the proximal femur. The samples were measured for their content of aluminium using a mass spectrometer. RESULTS: No significant association between the aluminium content in bone and femoral neck BMD, BMC or width could be found after multivariate adjustment. CONCLUSION: Our results indicate that the accumulated aluminium content in bone during life does not substantially influence the extent of osteoporosis

Aluminium dependent human diseases, and chelating properties of aluminium chelators for bio-medical applications

1. Introduction 2. Aluminium metabolism 2.1 Intestinal aluminium absorption 2.2 Aluminium transport in blood 2.3 Tissue distribution 2.4 Brain uptake and efflux 2.5 Aluminium excretion 3. Solution chemistry of aluminium 4. Chelating agents 5. Crystal structures of selected Al(III) complexes 5.1. Al-(6O) complexes 5.2. Al-(4O,2N) complexes 5.3. Al-(3O,3N) complexes 6. Reference

In-Stent Restenosis: Definition, Entity of the Problem, Etiopathogenesis and Treatment Options

In-stent restenosis (ISR) still represents a frequent limitation of percutaneous coronary intervention despite the introduction of latest-generation drug-eluting stents (DES), drastically lowering the overall incidence of ISR. Thus, the treatment of DES ISR remains a real brainteaser for interventional cardiologists